CKD-Associated Cardiovascular Mortality in the United States: Temporal Trends From 1999 to 2020

Kobo, Ofer; Abramov, Dmitry; Davies, Simon; Ahmed, Sofia B.; Sun, Louise Y.; Mieres, Jennifer H.; Parwani, Purvi; Siudak, Zbigniew; Spall, Harriette G.C. Van; Mamas, Mamas A.

doi:10.1016/j.xkme.2022.100597

Cited by 14 publications

(9 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current study expands on prior publications which describe trends in CVD mortality in the US over the last 20 years. Declines in CVD mortality were noted among the whole US population over the same time frame [ 14 ], with smaller declines in CVD mortality noted among patients with high-risk comorbid conditions such as CKD and diabetes [ 15 , 16 ]. However, the role of obesity as a contributor to CVD mortality has not been well characterized.…”

Section: Discussionmentioning

confidence: 99%

Has the first year of the COVID pandemic impacted the trends in obesity-related CVD mortality between 1999 and 2019 in the United States?

Qamar,

Abramov,

Bang

et al. 2024

International Journal of Cardiology Cardiovascular Risk and Pre

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Has the first year of the COVID pandemic impacted the trends in obesity-related CVD mortality between 1999 and 2019 in the United States?

Qamar,

Abramov,

Bang

et al. 2024

International Journal of Cardiology Cardiovascular Risk and Pre

Self Cite

View full text Add to dashboard Cite

“…This database has previously been used in several other studies to determine CVD mortality trends. 11 , 12 Patients with SU were identified with International Classification of Diseases, Tenth Revision, Clinical Modification ( ICD‐10‐CM ) codes provided in supplementary files, and patients with CVD were identified with ICD‐10‐CM codes I00‐I99 (diseases of the circulatory system) in patients ≥25 years of age as previously described. 12 , 13 , 14 Smoking/tobacco use was not included in primary analyses as a form of SU.…”

Section: Methodsmentioning

confidence: 99%

Temporal Trends in Substance Use and Cardiovascular Disease–Related Mortality in the United States

Minhas,

Kewcharoen,

Hall

et al. 2024

JAHA

Self Cite

View full text Add to dashboard Cite

Background There are limited data on substance use (SU) and cardiovascular disease (CVD)–related mortality trends in the United States. We aimed to evaluate SU+CVD–related deaths in the United States using the Centers for Disease Control and Prevention Wide‐Ranging, Online Data for Epidemiologic Research database. Methods and Results The Multiple Cause‐of‐Death Public Use record death certificates were used to identify deaths related to both SU and CVD. Crude, age‐adjusted mortality rates, annual percent change, and average annual percent changes with a 95% CI were analyzed. Between 1999 and 2019, there were 636 572 SU+CVD‐related deaths (75.6% men, 70.6% non‐Hispanic White individuals, 65% related to alcohol). Age‐adjusted mortality rates per 100 000 population were pronounced in men (22.5 [95% CI, 22.6–22.6]), American Indian or Alaska Native individuals (37.7 [95% CI, 37.0–38.4]), nonmetropolitan/rural areas (15.2 [95% CI, 15.1–15.3]), and alcohol‐related death (9.09 [95% CI, 9.07 to 9.12]). The overall SU+CVD‐related age‐adjusted mortality rates increased from 9.9 (95% CI, 9.8–10.1) in 1999 to 21.4 (95% CI, 21.2–21.6) in 2019 with an average annual percent change of 4.0 (95% CI, 3.7–4.3). Increases in SU+CVD‐related average annual percent change were noted across all subgroups and were pronounced among women (4.8% [95% CI, 4.5–5.1]), American Indian or Alaska Native individuals, younger individuals, nonmetropolitan areas, and cannabis and psychostimulant users. Conclusions There was a prominent increase in SU+CVD‐related mortality in the United States between 1999 and 2019. Women, non‐Hispanic American Indian or Alaska Native individuals, younger individuals, nonmetropolitan area residents, and users of cannabis and psychostimulants had pronounced increases in SU+CVD mortality.

show abstract

“…Cardiovascular disease is the leading cause of mortality among patients whose estimated glomerular filtration rate has decreased to less than 60 mL/min/1.73 m 2 5 6. In the USA, the age-adjusted mortality rate associated with CKD rose by 50% between 1999 and 2020; notably, 39% of all deaths were attributed to cardiovascular disease,5 but GBD reports did not indicate what percentage of those deaths were indirectly related to CKD. Furthermore, deaths from acute kidney injury (AKI), which co-occur with CKD, were not reported.…”

Section: Introductionmentioning

confidence: 99%

Global trends in chronic kidney disease-related mortality: a systematic review protocol

Tungsanga,

Ghimire,

Hariramani

et al. 2024

BMJ Open

View full text Add to dashboard Cite

IntroductionIn recent decades, all-cause mortality has increased among individuals with chronic kidney disease (CKD), influenced by factors such as aetiology, standards of care and access to kidney replacement therapies (dialysis and transplantation). The recent COVID-19 pandemic also affected mortality over the past few years. Here, we outline the protocol for a systematic review to investigate global temporal trends in all-cause mortality among patients with CKD at any stage from 1990 to current. We also aim to assess temporal trends in the mortality rate associated with the COVID-19 pandemic.Methods and analysisWe will conduct a systematic review of studies reporting mortality for patients with CKD following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We will search electronic databases, national and multiregional kidney registries and grey literature to identify observational studies that reported on mortality associated with any cause for patients with CKD of all ages with any stage of the disease. We will collect data between April and August 2023 to include all studies published from 1990 to August 2023. There will be no language restriction, and clinical trials will be excluded. Primary outcome will be temporal trends in CKD-related mortality. Secondary outcomes include assessing mortality differences before and during the COVID-19 pandemic, exploring causes of death and examining trends across CKD stages, country classifications, income levels and demographics.Ethics and disseminationA systematic review will analyse existing data from previously published studies and have no direct involvement with patient data. Thus, ethical approval is not required. Our findings will be published in an open-access peer-reviewed journal and presented at scientific conferences.PROSPERO registration numberCRD42023416084.

show abstract

CKD-Associated Cardiovascular Mortality in the United States: Temporal Trends From 1999 to 2020

Cited by 14 publications

References 41 publications

Has the first year of the COVID pandemic impacted the trends in obesity-related CVD mortality between 1999 and 2019 in the United States?

Has the first year of the COVID pandemic impacted the trends in obesity-related CVD mortality between 1999 and 2019 in the United States?

Temporal Trends in Substance Use and Cardiovascular Disease–Related Mortality in the United States

Global trends in chronic kidney disease-related mortality: a systematic review protocol

Contact Info

Product

Resources

About